Angiotensin-Converting Enzyme: I. New Strategies for Assay

Angiotensin-converting enzyme: I. New strategies for assay

The disposition of converting enzyme (kininase II) on the luminal surface of pulmonary endothelial cells is well established. Further, it is known that there is a net conversion of angiotensin I into angiotensin II as blood passes through the lungs. However, little is known about modulations of converting enzyme activity that may arise through, e.g., changes in the quality of inhalants, blood f...

Angiotensin Converting Enzyme in Sarcoidosis

Angiotensin I converting enzyme.

• Interest in particular biologically active substances waxes and wanes. Investigators rush into a newly opened field, solve a few problems, and frequently raise more; then they rush out to follow more promising developments elsewhere. However, interest in angiotensins generally has persisted and increased. Observation of the actions of angiotensins has led to the study of enzymes involved in t...

New mass spectrometric assay for angiotensin-converting enzyme 2 activity.

A novel assay was developed for evaluation of mouse angiotensin-converting enzyme (ACE) 2 and recombinant human ACE2 (rACE2) activity. Using surface-enhanced laser desorption/ionization time of flight mass spectrometry (MS) with ProteinChip Array technology, ACE1 and ACE2 activity could be measured using natural peptide substrates. Plasma from C57BL/6 mice, kidney from wild-type and ACE2 knocko...

Inhibitor binding assay for angiotensin-converting enzyme.

We describe a new principle for the determination of enzymes, here applied to angiotensin-converting enzyme (ACE, EC 3.4.15.1) in human serum. The enzyme inhibitor binding assay is based on specific binding of labeled inhibitor to the active center of the enzyme. Serum (10-15 microL) is incubated with 125I-labeled ACE inhibitor (" 351A ," a p- hydroxybenzamidine derivative of N-(1-carboxy-3-phe...